Diaxonhit Signs a Research Service Agreement with Boehringer Ingelheim

05-Sep-2013 - France

Diaxonhit enters into a research service agreement with Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology. Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray™ discovery platform, with the aim of adding further to its comprehensive research programme to develop cancer drugs.

“This agreement with Boehringer Ingelheim demonstrates the continued interest in and effectiveness of our SpliceArrayTM discovery platform, and the expertise we have efficiently developed to exploit our comprehensive transcriptomic data for new target discovery ” said Loïc Maurel M.D., President of Diaxonhit’s Management Board.

Financial terms were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances